“The European Commission needs to develop a proper and integrated strategy on nutrition backed by a significant increase in funding, according to a report” on the E.U. and nutrition development policy that is supported by international organizations, companies and non-governmental organizations, the Guardian reports. The newspaper notes that the U.N. Food and Agriculture Organization estimates up to one billion people are undernourished worldwide, and the World Food Programme says it will take $11.8 billion annually to address 90 percent of child malnutrition cases.
Private Sector Involvement
The Affordable Medicines Facility-malaria (AMFm) — an innovative financing mechanism that subsidizes the cost of artemisinin-based combination therapies (ACTs) in order to expand access to the most effective treatment for malaria — “brought more than 100 million doses of malaria drugs to clinics and pharmacies in 2011” and “also increased access to the top malaria medicines by 26 to 52 percent in six countries,” according to results from the first phase of the program, which is hosted and managed by the Global Fund to Fight AIDS, Tuberculosis and Malaria, NPR’s “Shots” blog reports. The results of the evaluation, released on Wednesday in Washington, D.C., do not estimate how many lives were saved because of improved access to effective malaria medications, as “AMFm ran for only a year and half in most countries,” according to the blog. “The AMFm negotiated with drugmakers to reduce ACTs prices, and then the Global Fund subsidized the initial purchasing of the drugs by clinics and pharmacies,” the blog notes.
French drug maker Sanofi on Thursday announced a new three-year research collaboration agreement with the TB Alliance “to accelerate the discovery and development of novel compounds against tuberculosis,” RTTNews reports (9/20). “According to company material, the projects will explore a compound which researchers believe has potential to treat all forms of tuberculosis, investigate another class of natural derivatives that has shown ‘impressive’ activity against tuberculosis bacteria, and identify future candidates for development among chemical compounds in Sanofi’s collection,” the Center for Global Health Policy’s “Science Speaks” blog writes (Barton, 9/20). RTTNews notes, “Sanofi, which discovered rifampicin in the early 1960s, markets several anti-tuberculosis drugs” (9/20).
The Coca-Cola Company and the Global Fund to Fight AIDS, Tuberculosis and Malaria have announced the expansion of a pilot project, called “Project Last Mile,” that uses Coca Cola’s “‘expansive global distribution system and core business expertise’ to help deliver critical medicines to remote parts of the world, beginning in rural Africa,” Pharma Times reports. “The public-private partnership was established in 2010 to help Tanzania’s government-run medicine distribution network, Medical Stores Department, build a more efficient supply chain by using Coca-Cola’s” delivery system model, the news service writes, adding, “The latest phase of the partnership, developed in cooperation with the likes of the Bill & Melinda Gates Foundation, Accenture and Yale University, will increase the availability of critical medicines to 75 percent of Tanzania and expand the initiative to Ghana and Mozambique” (Grogan, 9/26).
“India has had a positive global impact through its supply of vast quantities of low-cost, good-quality generic medicines, which have saved or prolonged millions of lives … [b]ut there are also many factors that may hinder the continuation of the [country's] role as chief supplier of medicines to developing countries,” Martin Khor, executive director of the South Centre in Geneva, writes in an Inter Press Service opinion piece. He examines the history of generic drug production in India and says the 1995 World Trade Organization TRIPS agreement negatively affected the country’s ability to produce generic drugs. Though “India has one of the best patent laws in the world that still gives some space to its producers to make generic drugs, … it is also true that the old policy space has been eroded because many new drugs have, since 2005, been patented by multinational companies that are selling them at exorbitant prices,” Khor writes.
“Severe droughts, rising grain prices and food shortages — the latest headlines are an urgent call for action,” and “it is time to step up our response,” Suma Chakrabarti, president of the European Bank for Reconstruction and Development (EBRD), and Jose Graziano da Silva, director-general of the U.N. Food and Agriculture Organization (FAO), write in a Wall Street Journal opinion piece. On September 13, the EBRD and FAO will convene the Private Sector for Food Security Conference in Istanbul, Turkey, “the largest and most important gathering of companies and decision-makers in agribusiness from the Caspian and Black seas to the Mediterranean … [to] discuss the key role of the private sector in feeding the world,” they note. “The simple truth is that the world needs more food, and that means more production,” they state, adding, “The private sector can be the main engine of such growth.”
As the BRIC countries — Brazil, Russia, India, and China — invest more in innovations in health technologies and other areas, “many are looking to these countries to correct the global health research and development (R&D) imbalance that leaves the poor without needed products such as an improved tuberculosis (TB) vaccine or tests to help diagnose patients in remote rural settings,” David de Ferranti, president of Results for Development Institute (R4D), writes in the Huffington Post Blog. Writing that “India, which has already played such an important role in manufacturing affordable antiretroviral drugs, vaccines, and other essential health commodities for developing countries,” de Ferranti asks whether India “is … ready to play a leading role in health R&D?”
In this post in the Center for Strategic & International Studies’ (CSIS) “Smart Global Health” blog, Rhonda Zygocki, executive vice president of policy and planning at Chevron, responds to questions about Chevron’s presence at the XIX International AIDS Conference (AIDS 2012) in Washington, D.C., last week, writing that such questions “give me an opportunity to talk about the critical role everyone plays in the global fight against this epidemic, including Chevron, as well as the ways collaborative partnerships will lead to the elimination of AIDS.” She highlights the company’s HIV prevention efforts, including a pledge last year of $20 million to the U.N.’s mission to eliminate mother-to-child HIV transmission by 2015, and continues, “Individuals, non-profit organizations, medical practitioners, representatives of governments, and companies from the private sector joined together in Washington, D.C., with the same vision: to create an HIV-free generation and eliminate AIDS around the world” (8/1).
“When you’re dealing with a global public health crisis, having an international presence isn’t just advisable — it is imperative,” Margaret McGlynn, president and CEO of the International AIDS Vaccine Initiative (IAVI), writes in this post in USAID’s “Impact” blog, adding, “That’s why [IAVI], in partnership with USAID, has worked diligently over the past several years to establish itself as a truly global non-profit partner.” She continues, “IAVI has created an enviable network of research centers in sub-Saharan Africa dedicated to assessing novel AIDS vaccine candidates in clinical trials and conducting supporting epidemiological studies on HIV,” and writes that these “partnerships have made meaningful contributions to the research capacity of many developing countries — a capability that is now helping local researchers tackle other diseases” (8/13).
The Associated Press examines the debate over the future of the Affordable Medicines Facility-malaria (AMFm), after the recent release of two papers evaluating the program’s effectiveness. AMFm was established in 2010 as “a pilot project to subsidize artemesinin combination drugs, the most effective malaria treatment,” the AP writes, noting the $460 million program is managed by the Global Fund to Fight AIDS, Tuberculosis and Malaria. “Last week, a report by Oxfam, an international charity, labeled the program a failure and said there was no proof it had saved lives because officials didn’t track who received the drugs,” the news service writes, adding, “But in another paper published Wednesday in the journal Lancet, experts insisted the program was ‘an effective mechanism’ to lower the price of preferred malaria drugs and make them widely available.” The Global Fund is scheduled to discuss the future of the program at a meeting next month, according to the AP (Cheng, 10/31).